3 ms·
Weird. Are you sure the tweets talk about the same study? The study in the article didn’t look at antibody response, but at the clinical outcome - just like th
by kolinko 6y ago
Weird. Are you sure the tweets talk about the same study?
The study in the article didn’t look at antibody response, but at the clinical outcome - just like the original Phase III studies did, just with a smaller group of people.
As for the claim that we don’t know how the vaccine protects from hospitalisations - if there is literally no difference in mild cases, why would there be any difference in severe?
Is there a single vaccine for any disease that offers no protection against mild cases, but a high protection from severe?
- 360walk 6y agoRegarding the question about how the vaccine could protect against severe but not mild infection, I think they answer that here: > Antibodies can prevent infection, your T cell-responses ensure that those antibodies keep doing their job and they kick in after you're infected OR oh my goodness stop the presses- VACCINATED (how about them apples). In other words, while robust T-cells responses cannot protect you from a mild or moderate infection sometimes (think cough, sniffles, etc.) they can however proliferate rapidly and prevent the build up of viral load. Psst- you want this to be LOW. VL drives disease severity.
- MrAlex94 6y ago> Weird. Are you sure the tweets talk about the same study? Yes, this is in reference to B.1.351 and the AZ SA study.